Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Quick Listen: Scrip’s Five Must-Know Things

Executive Summary

Join us for a brief audio tour around the past week's key developments in the global biopharma industry, in this podcast version of Scrip's Five Must-Know Things.

Join us in this regular podcast covering major industry events over the past week, as brought to you by Scrip's global team, this time for the business week ended 20 November 2020. 

In this episode, we look at results and plans for coronavirus vaccines, a US product setback, PCSK9 developments, and the latest progress in NASH.



These and other Informa Pharma Intelligence podcasts are available via SoundCloud, Apple Podcasts, Google Play and TuneIn, and also via smart speakers - just make sure you have set up at least one of these platforms as your default player for podcasts and then ask for "Pharma Intelligence podcasts".

Articles mentioned in this episode:

(Also see "Moderna Aces COVID-19 Vaccine Results With 94.5% Efficacy" - Scrip, 16 Nov, 2020.)

(Also see "Pfizer Pilots COVID-19 Immunization Plan In Four States As ‘Dry Run’" - Scrip, 17 Nov, 2020.)

(Also see "Sanofi Stunned As FDA Says No To CAD Drug Sutimlimab" - Scrip, 16 Nov, 2020.)

(Also see "Ionis, AstraZeneca To Use Real-World Data To Accelerate RNA-Targeting Cholesterol Drug" - Scrip, 13 Nov, 2020.)

(Also see "Year Of NASH Upheaval Means Incremental Data At AASLD" - Scrip, 18 Nov, 2020.)

Details of the FDA/CMS summit on 7-9 December as mentioned in the podcast can be found here.


Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts